123 related articles for article (PubMed ID: 38721770)
1. A BRD4-Targeting Photothermal Agent for Controlled Protein Degradation.
Shi M; Li Y; Pan W; Fu Z; Wang K; Liu X; Li N; Tang B
Angew Chem Int Ed Engl; 2024 May; ():e202403258. PubMed ID: 38721770
[TBL] [Abstract][Full Text] [Related]
2. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals.
Li R; Hu X; Shang F; Wu W; Zhang H; Wang Y; Pan J; Shi S; Dong C
Acta Biomater; 2022 Aug; 148():218-229. PubMed ID: 35705171
[TBL] [Abstract][Full Text] [Related]
3. Low Power Single Laser Activated Synergistic Cancer Phototherapy Using Photosensitizer Functionalized Dual Plasmonic Photothermal Nanoagents.
Younis MR; Wang C; An R; Wang S; Younis MA; Li ZQ; Wang Y; Ihsan A; Ye D; Xia XH
ACS Nano; 2019 Feb; 13(2):2544-2557. PubMed ID: 30730695
[TBL] [Abstract][Full Text] [Related]
4. KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
Qiang Y; Fan J; Xie C; Yan L; Song X; Zhang N; Lin Y; Xiong J; Zhang W; Liu Y; Wei L; Li Y; Chen S; Liang K; Li F
Cancer Res; 2024 Apr; 84(8):1252-1269. PubMed ID: 38285760
[TBL] [Abstract][Full Text] [Related]
5. Advances in Nanomaterial-Mediated Photothermal Cancer Therapies: Toward Clinical Applications.
Han HS; Choi KY
Biomedicines; 2021 Mar; 9(3):. PubMed ID: 33809691
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
7. Molecular Targeting-Mediated Mild-Temperature Photothermal Therapy with a Smart Albumin-Based Nanodrug.
Gao G; Jiang YW; Sun W; Guo Y; Jia HR; Yu XW; Pan GY; Wu FG
Small; 2019 Aug; 15(33):e1900501. PubMed ID: 31282114
[TBL] [Abstract][Full Text] [Related]
8. Near-Infrared Fluorescent Sorbitol Probe for Targeted Photothermal Cancer Therapy.
Lee S; Jung JS; Jo G; Yang DH; Koh YS; Hyun H
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31480639
[TBL] [Abstract][Full Text] [Related]
9. Ce6-Modified Carbon Dots for Multimodal-Imaging-Guided and Single-NIR-Laser-Triggered Photothermal/Photodynamic Synergistic Cancer Therapy by Reduced Irradiation Power.
Sun S; Chen J; Jiang K; Tang Z; Wang Y; Li Z; Liu C; Wu A; Lin H
ACS Appl Mater Interfaces; 2019 Feb; 11(6):5791-5803. PubMed ID: 30648846
[TBL] [Abstract][Full Text] [Related]
10. A Golgi Apparatus-Targeted Photothermal Agent with Protein Anchoring for Enhanced Cancer Photothermal Therapy.
Shi M; Fu Z; Pan W; Wang K; Liu X; Li N; Tang B
Adv Healthc Mater; 2024 Mar; ():e2303749. PubMed ID: 38483042
[TBL] [Abstract][Full Text] [Related]
11. Ataxia telangiectasia mutated inhibitor-loaded copper sulfide nanoparticles for low-temperature photothermal therapy of hepatocellular carcinoma.
Cai H; Dai X; Guo X; Zhang L; Cao K; Yan F; Ji B; Liu Y
Acta Biomater; 2021 Jun; 127():276-286. PubMed ID: 33812073
[TBL] [Abstract][Full Text] [Related]
12. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
[TBL] [Abstract][Full Text] [Related]
13. A mitochondria-targeted thiazoleorange-based photothermal agent for enhanced photothermal therapy for tumors.
Bian W; Pan Z; Wang Y; Long W; Chen Z; Chen N; Zeng Y; Yuan J; Liu X; Lu YJ; He Y; Zhang K
Bioorg Chem; 2021 Aug; 113():104954. PubMed ID: 34023651
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional theranostic nanoplatform loaded with autophagy inhibitor for enhanced photothermal cancer therapy under mild near-infrared irradiation.
Shi M; Liu Y; Huang J; Chen Z; Ni C; Lu J; Zhang Y; Liu Z; Bai J
Biomater Adv; 2022 Jul; 138():212919. PubMed ID: 35913232
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
16. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
17. Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer.
Shao F; Pan Z; Long Y; Zhu Z; Wang K; Ji H; Zhu K; Song W; Song Y; Song X; Gai Y; Liu Q; Qin C; Jiang D; Zhu J; Lan X
J Nanobiotechnology; 2022 May; 20(1):243. PubMed ID: 35614462
[TBL] [Abstract][Full Text] [Related]
18. Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects.
Kim YH; Kim M; Kim JE; Yoo M; Lee HK; Lee CO; Yoo M; Jung KY; Kim Y; Choi SU; Park CH
Oncol Lett; 2021 Jun; 21(6):473. PubMed ID: 33907583
[TBL] [Abstract][Full Text] [Related]
19. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4.
Yang L; Jing Y; Xia X; Yin X
J Oncol; 2023; 2023():9904143. PubMed ID: 38130463
[TBL] [Abstract][Full Text] [Related]
20. Biomimetic black phosphorus nanosheets codeliver CDK9 and BRD4 inhibitors for gastric cancer targeted therapy.
Zhang Z; Zhang X; Ren Z; Wu X; Qiao H; Huang X; Zhao W; Zhang Y; Lou K
J Mater Chem B; 2023 Jul; 11(26):6131-6140. PubMed ID: 37345728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
